CES3 Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q6UWW8 |
---|
Gene ID | 23491 |
---|---|
Other Names | Carboxylesterase 3, Liver carboxylesterase 31 homolog, CES3 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | CES3 |
---|---|
Function | Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Shows low catalytic efficiency for hydrolysis of CPT-11 (7-ethyl-10-[4-(1-piperidino)-1-piperidino]- carbonyloxycamptothecin), a prodrug for camptothecin used in cancer therapeutics. |
Cellular Location | Endoplasmic reticulum lumen. |
Tissue Location | Expressed in liver, colon and small intestine. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Carboxylesterase 3 is a member of a large multigene family. The enzymes encoded by these genes are responsible for the hydrolysis of ester- and amide-bond-containing drugs such as cocaine and heroin. They also hydrolize long-chain fatty acid esters and thioesters. The specific function of this enzyme has not yet been determined; however, it is speculated that carboxylesterases may play a role in lipid metabolism and/or the blood-brain barrier system.
References
Sanghani, S.P., et al. Protein Pept. Lett. 16(10):1207-1214(2009) Fukami, T., et al. Pharmacogenet. Genomics 18(10):911-920(2008) Sanghani, S.P., et al. Drug Metab. Dispos. 32(5):505-511(2004) Sanghani, S.P., et al. Clin. Cancer Res. 9(13):4983-4991(2003)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.